ERBB2 and neoplasm: Several targeted liposomes have shown increased efficacy compared to non-targeted liposomes despite identical EPR-driven levels of tumor accumulation, including the antibody-targeted anti-HER2 and anti-EGFR formulations of liposomal doxorubicin [37,38].